[Accessed on February 12, 2026] Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Hepatic Uncommon (0.1% to 1%): Acute gallbladder disease (cholelithiasis, biliary colic, cholecystectomy) Hypersensitivity Common (1% to 10%): Hypersensitivity reactions (e.g., urticaria, eczema) Postmarketing reports : Anaphylaxis, angioedema Immunologic Very common (10% or more): Anti-drug antibodies (up to 51%) Common (1% to 10%): Neutralizing antibodies Local Common (1% to 10%): Injection site reactions Metabolic Very common (10% or more): Hypoglycemia (up to 19%), decreased appetite (up to 11%) Common (1% to 10%): Hyperglycemia Hypoglycemia (glucose level less than 54 mg/dL) occurred more frequently when this drug was used in combination with a sulfonylurea (up to 13% of patients in a clinical trial)
Most side effects are digestive changes, but it is often mild, temporary, and tend to improve as your body adjusts to treatment
The trial data shows slightly higher hair loss rates with tirzepatide (about 5%) versus semaglutide (about 3%), but tirzepatide also produces more weight loss, which to me is the more likely explanation
